Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q3 FY2024 Earnings Presentation
30 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, February 2024
Slide 1: IOL Chemicals and Pharmaceuticals Limited Q3 & 9M FY24 Investor Presentation
IOL Chemicals and Pharmaceuticals Limited Q3 & 9M FY24 Investor Presentation February 2024
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by IOL Chemicals & Pharmaceuticals Limited (the “Companies”, IOL) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on i
Slide 3: Table of Contents
Table of Contents 01 IOLCP at a glance 02 Financial Highlights 03 Company Overview Quarterly & nine monthly Income Statement The Journey About IOL Chemicals and Pharmaceuticals Ltd. Growing top-line Core management team Q3 FY24 & 9M-FY24 Performance Building Assets Board of Directors Geographical &
Slide 4: IOL Chemicals & Pharma - Overview
IOL Chemicals & Pharma - Overview Incorporated in 1986, IOLCP is one of the leading API Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Team size of 2700+ employees Credit Rating: A+, outlook; stable (Care Ratings Limited) Debt free
Slide 5: Q3 & 9M-FY24 Performance
Q3 & 9M-FY24 Performance Q3FY24 Financial Performance 528.8 52.9 10.0% • Received CEP Certificate for Losartan Potassium issued Total Income (Rs. cr) EBITDA (Rs. cr) EBITDA Margin by EDQM which will enable higher export to European market • The Board declared an Interim Dividend of Rs.5/- per 23.2 4
Slide 6: Geographical and Segmental highlights
Geographical and Segmental highlights Chemical Segment (Rs. crore) Pharma Segment (Rs. crore) 218 219 214 233 12 400 368 100 211 349 332 200 303 287 10 80 11 8 300 80 150 60 3 4 200 100 1 50 40 50 -1 0 35 50 100 35 20 0 -4 0 0 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Rev
Slide 7: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 8: Quarterly & Nine monthly Income Statement
Quarterly & Nine monthly Income Statement Particulars (Rs. Cr) Q3 FY24 Q3 FY23 YoY Q2 FY24 9M FY24 9M FY23 YoY Revenues 520.4 523.5 -0.6% 545.3 1,628.9 1,629.9 -0.1% Other Income 8.4 6.6 7.1 22.6 16.9 Total Income 528.8 530.1 -0.2% 552.4 1,651.5 1,646.8 0.3% Total Expenses 475.9 480.4 481.2 1,447.4
Slide 9: Growing top-line
Growing top-line Particulars (Rs. Cr) FY19 FY20 FY21 FY22 FY23 9M-FY24 Revenues 1,685.3 1,894.5 1,967.0 2,184.0 2,217.1 1,628.9 Other Income 10.4 16.0 24.3 32.0 25.6 22.6 Total Income 1,695.7 1,910.5 1,991.3 2,216.0 2,242.7 1,651.5 Total Expenses 1,275.7 1,320.6 1,375.2 1,927.6 1,990.6 1,447.4 EBITD
Slide 10: Building assets
Building assets Balance Sheet (Rs. Cr) FY19 FY20 FY21 FY22 FY23 H1-FY24 Shareholders' Funds 474.3 813.5 1260.4 1390.3 1506.6 1588.8 Debt 284.0 56.0 0.0 0.0 0.0 0.0 Total Non-current Liabilities 20.8 79.7 59.1 56.6 58.1 61.5 Total Current Liabilities 162.8 220.6 290.6 513.4 455.9 429.9 Equity & Liabi
Slide 11: Cash Flow Statement
Cash Flow Statement Particulars (Rs. Cr) FY19 FY20 FY21 FY22 FY23 H1-FY24 Profit before tax 336.15 533.24 571.39 222.84 189.49 112.63 Adjustments for: Non Cash Items / Other 82.35 51.93 27.15 33.12 44.42 29.60 Investment or Financial Items Operating profit before working capital changes 418.50 585.1
Slide 12: 5-years Performance
5-years Performance Operational Revenue (Rs Cr) EBITDA (Rs. Cr) and EBITDA Margin (%) PAT (Rs. Cr) and PAT Margin (%) 2,216 2,243 30.9% 30.9% 22.3% 1,911 1,991 1,696 24.8% 18.9% 1,652 11.2% 14.0% 13.0% 12.4% 7.5% 6.5% 6.2% 420 590 616 288 252 204 237 361 445 166 140 107 FY19 FY20 FY21 FY22 FY23 9M-F
Slide 13: Diversified revenue base
Diversified revenue base FY19 FY23 9M-FY24 568, 34% 955, 43% 659, 40% 476, 22% 334, 21% 128, 7% 989, 59% 786, 35% 636, 39% Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's 13 * Amt in Rs.crore
Slide 14: Company Overview
COMPANY OVERVIEW
Slide 15: The Journey
The Journey ▪ 2009 - Commencement of ▪ 2015 - USFDA, EIR for ▪ 2019 - Unit-06 for ▪ 1996 - Commencement of IBB, MCA and Acetyl ▪ Commenced Ibuprofen Pantoprazole (Dedicated) Ethyl Acetate Plant Chloride Plants commercial production ▪ 2016 - Unit-03 for new ▪ 2020 - Unit-07 Metformin ▪ 1999 - Commenc
Slide 16: Core management team
Core management team Varinder Gupta (Managing Director) ▪ Wide and rich experience of more than 35 years in the chemical & fertilizer industry and along Vikas Gupta with a comprehensive approach and strong (Joint Managing Director) Pharma API industry oversight has paved a way ▪ Academically equippe
Slide 17: Board of Directors
Board of Directors Rajender Mohan Malla (Chairman and Independent Director) ▪ With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs Harpal Singh ▪ In his most recent executive roles, he was MD & (Independent Director) CEO of PTC I
Slide 18: Certifications and Accreditations
Certifications and Accreditations Approved USFDA facility since EUGMP Certification in 2013, Certificate of Suitability from Certified Halal in accordance 2015, recertified in 2019 2017 & Recertification in 2020 Certificate of DMF Registration EDQM with Shariah Board Guidelines From MFDS Korea Certi
Slide 19: Business Overview
BUSINESS OVERVIEW
Slide 20: Pharmaceuticals – Building API portfolio
Pharmaceuticals – Building API portfolio IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen having a capacity of 12000+ MT • Dedicated USFDA approved facilities for Ib
Slide 21: Specialty chemicals – capitalizing on global demand
Specialty chemicals – capitalizing on global demand IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 TPA Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 1,00,000 TPA • Commenced
Slide 22: Manufacturing facilities
Manufacturing facilities API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC 1 3 5 intermediates & Specialty chemicals in Dedicated and multiproduct blocks system, PSA Nitrogen & Purified water continuous product delivery manner involved in manufacturing of APIs along with
Slide 23: Ensuring a Sustainable Tomorrow Through ESG Initiatives
Ensuring a Sustainable Tomorrow Through ESG Initiatives Environment • Committed to ensure that our operations have minimal • Our continuous efforts have resulted in a 4.58% impact on the environment • Constantly monitoring environmental footprints and reduction in Scope-01 greenhouse gas (GHG) emiss
Slide 24: Industry Overview
INDUSTRY OVERVIEW
Slide 25: Pharmaceuticals – Emerging strongly out of pandemic
Pharmaceuticals – Emerging strongly out of pandemic Indian API Market World Pharmaceutical Industry • Active Pharmaceutical Ingredient is a crucial segment of the pharma industry, contributing to around 35% of the market • India is the 3rd largest producer of API accounting $1.5 3-6% $2.4 for an 8%
Slide 26: Specialty Chemicals - an era of sustained robust growth
Specialty Chemicals - an era of sustained robust growth • India is expected to become a $1,000 Bn chemicals market by 2040, currently constituting 3.4% share of the global Indian Specialty Chemical Industry chemical market • Specialty Chemical account for 20% of the global chemical Specialty industr
Slide 27: Way Forward
WAY FORWARD
Slide 28: Charting a path to success
Charting a path to success Four pronged strategy for growth Focus on Capacity Improved Expanding Regulated expansion in asset Non-Ibuprofen Pharma & utilization Markets Business Chemicals During the last five years During the last five years, Increased contribution Added more than 10 the share of re
Slide 29: Expanding the non-Ibuprofen business
Expanding the non-Ibuprofen business (Analgesic and Antipyretic drugs) Multi Product facility focused on Paracetamol, with an Regulatory Filings: CEP installed capacity of approved; US DMF filed 3,600 MT/Annum, with a backward integration process (Antiplatelet drug, used in cardiovascular (Anticonsu
Slide 30: Thank You
Thank You Company : Investor Relations Advisors : IOL Chemicals and Adfactorspr Pvt. Ltd. Pharmaceuticals Ltd. Mr. Pardeep Kumar Khanna, Darshan Mankad CFO darshan.mankad@adfactorspr.com pardeepkhanna@iolcp.com Hanishi Shah hanishi.shah@adfactorspr.com www.iolcp.com www.adfactorspr.com
IOL Chemicals and Pharmaceuticals — Q3 FY2024 Earnings Presentation on 6ix